Latest Headlines

  1. BD Launches BD Intevia 1mL Two-Step Disposable Autoinjector – A Robust Platform Device Combining Autoinjector And Pre-Fillable Syringe In One Integrated System

    BD (Becton, Dickinson and Company), a leading global medical technology company, recently announced the launch of the BD Intevia 1mL two-step disposable autoinjector, a robust platform device combining autoinjector and pre-fillable syringe in one integrated system.

  2. Medtronic Submits InterStim Micro Neurostimulator And SureScan MRI Leads For FDA Approval

    Medtronic plc (NYSE:MDT) today announced it has filed a pre-market approval (PMA) supplement with the United States Food and Drug Administration (FDA) for approval of its InterStim™ Micro neurostimulator and also its InterStim™ SureScan™ MRI leads.

  3. Qosina Is The One-Stop Source For Tuohy Borst Adapters

    Qosina is pleased to carry over 40 different configurations of tuohy borst adapters in sizes ranging from 0-18 FR.

  4. Dance Biopharm Rebrands, Now Aerami Therapeutics

    Dance Biopharm, a clinical-stage company reimagining the treatment of chronic diseases with inhaled therapies, today announced it is rebranding as Aerami Therapeutics and moving its headquarters to Durham, North Carolina.

  5. MKS Announces Ophir® Large Aperture Laser Power/Energy Sensor For Pulsed Lasers

    MKS Instruments, Inc. (NASDAQ: MKSI), a global provider of technologies that enable advanced processes and improve productivity, has announced the Ophir® L2000W-PF-120 Laser Power/Energy Sensor, a water-cooled sensor for measuring large pulsed lasers. The thermal sensor measures powers from 1W to 2000W and energies from 6J to 6000J over the spectral range of 0.3µm to 2.2µm. The L2000W-PF-120 features a large 120mm aperture to accommodate high energy densities and short pulses. A fast, 7 sec response time balances the need to measure fast drifts and instabilities with the ability to handle high energy levels.

  6. Protolabs Adds Carbon Technology To Its 3D Printing Service

    Digital manufacturer Protolabs (NYSE: PRLB) has added the Carbon platform to its portfolio of production-grade additive manufacturing technologies. With Carbon Digital Light Synthesis™ (DLS), Protolabs’ customers can move into production faster and more cost-efficiently than ever before with 3D printing.

  7. Phillips-Medisize Enters Agreement with Global Pharmaceutical Company to Acquire Exclusive Ownership of Patents for an Innovative Mini-tablet Dispenser

    Phillips-Medisize, a Molex company, announced today an agreement with a Global Pharmaceutical Company, where Phillips-Medisize acquired exclusive ownership of patents supporting an innovative mini-tablet dispenser to accommodate the varied and customized oral dispensing needs of patients. This press release features multimedia. View the full release here: Mini-tablet Dispenser (Photo: Business Wire) “Through its unique working principle, the mini-tablet dispenser will be valuable in pediatrics, geriatrics and oncology where patients often require highly flexible

  8. Qosina President And CEO Scott Herskovitz Joins CEWIT Medical Advisory Board At Stony Brook University

    Qosina is pleased to announce that Scott Herskovitz, President and CEO, has joined the Medical Advisory Board (MAB) of the Center of Excellence in Wireless and Information Technology (CEWIT) at Stony Brook University.

  9. FDA Grants Breakthrough Designation To SoniVie’s TIVUS System To Treat Pulmonary Arterial Hypertension

    SoniVie, an Israeli company developing a novel system for the treatment of PAH, today announced that it has been granted Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for the Therapeutic Intra-Vascular Ultrasound (TIVUS) System in patients with PAH.

  10. Innovenn Launches New Human Factors Business Under The Name Improvita And Opens New State Of The Art Testing Lab

    Innovenn, a leader in Digital Therapeutics, has separated its human factors testing business under a new name Improvita which means; To Improve Life.  Innovenn will now focus purely on digital health care solutions including digital therapeutics and other software to help diagnose, prognose and manage patient care for those with rare diseases. Improvita will focus on human factors testing, ethnographics, user interface testing and user experience testing for medical devices, software as a medical device and combination drug / medical device products. To support the growing business, Improvita also opened a new state of the art testing lab in Madison, Wisconsin.